| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Actinonin is a naturally occurring antibacterial agent isolated from Actinomyces with antibiotic and anti-tumor activity. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities.
| ln Vitro |
In different human tumor cell lines, actinonin inhibits cell proliferation. The compounds had IC50 values of 4, 6.9, 12.8, 16.6, 27.4, 15.7, and 49.3 μM for Raji cells, MDA-MB-468 cells, PC3 cells, SK-LC-19 cells, Hela cells, HT-1080 cells, and AL67 cells, in that order[1]. Actinonin's primary target, HsPDF, is inhibited in the mitochondria by this protein, which causes tumor cells to die. In a dose- and time-dependent manner, actinonin administration of cells resulted in ATP depletion and tumor-specific mitochondrial membrane depolarization[1]. All three types (Zn-, Ni-, and Fe-) of peptide deformylases from S. aureus and E. coli bacteria are strongly inhibited by actinonin. The IC50 values for actinonin under test conditions are, respectively, 90, 3, 0.8, and 11 nM for Zn-PDF (E. coli), Ni-PDF (E. coli), Fe-PDF (E. coli), and Ni-PDF (S. aureus[2]. Actinonin exhibits antibacterial activity against Gram-positive bacteria, such as S. aureus (MIC value: 8–16 μg/mL), Streptococcus pyogenes (MIC value: 8 μg/mL), and Streptococcus epidermidis (MIC value: 2-4 μg/mL). Actinonin exhibits antibacterial activity against fastidious Gram-negative bacteria, including H. influenzae (MIC value of 1-2 μg/mL), Moraxella catarrhalis (MIC value of 0.5 μg/mL), and Neisseria gonorrhoeae (MIC value of 1-4 μg/mL). Actinonin exhibits high activity against the efflux pump mutants of H. influenzae acr (MIC value of 0.13 μg/mL) and E. coli acr (MIC value of 0.25 μg/mL)[2].
|
|---|---|
| ln Vivo |
Mice have been given actinonin as an antibiotic at levels up to 400 mg/kg without risk. Actinonin exhibits anticancer action in vitro, however it does not seem to be very harmful to normal tissues. It is noteworthy that actinonin, administered i.p. or orally, significantly reduces tumor growth in a CWR22 human prostate tumor xenograft model in naked mice. The animals exhibit no symptoms of toxicity while receiving treatment[1].
|
| References | |
| Additional Infomation |
Actinonin has been reported in Streptomyces with data available.
|
| Molecular Formula |
C19H35N3O5
|
|---|---|
| Molecular Weight |
385.4983
|
| Exact Mass |
385.257
|
| CAS # |
13434-13-4
|
| PubChem CID |
443600
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Melting Point |
137-139ºC
|
| Index of Refraction |
1.513
|
| LogP |
0.59
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
27
|
| Complexity |
498
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO
|
| InChi Key |
XJLATMLVMSFZBN-VYDXJSESSA-N
|
| InChi Code |
InChI=1S/C19H35N3O5/c1-4-5-6-8-14(11-16(24)21-27)18(25)20-17(13(2)3)19(26)22-10-7-9-15(22)12-23/h13-15,17,23,27H,4-12H2,1-3H3,(H,20,25)(H,21,24)/t14-,15+,17+/m1/s1
|
| Chemical Name |
(2R)-N'-hydroxy-N-[(2S)-1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~129.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (12.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (12.97 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (12.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5940 mL | 12.9702 mL | 25.9403 mL | |
| 5 mM | 0.5188 mL | 2.5940 mL | 5.1881 mL | |
| 10 mM | 0.2594 mL | 1.2970 mL | 2.5940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
